Offers for both GS GIR and JP ER for Summer 2020, but unsure which to choose. I want my decision to be based on:
* Exit Opps (Probably the same for both)
* Career Development (Not sure)
* Research Quality (I have heard JP >> GS, but unsure of this)
Thoughts?
This is in London btw if that matters.
| +81 | Q&A - Buyside Equity Research Analyst/PM | 29 | 4h | |
| +32 | How the heck do you learn all of this stuff? | 5 | 6d | |
| +28 | My experience on the sell side | 20 | 1w | |
| +28 | Getting Frustrated | 10 | 3w | |
| +26 | What’s my next move? | 7 | 7h | |
| +18 | Biotech ER vs IB | 16 | 3w | |
| +14 | Heard they don’t model at Oppenheimer | 10 | 1w | |
| +14 | Data Science to PM | 8 | 3d | |
| +14 | Am i fairly compensated? | 8 | 15h | |
| +13 | ER time line and ways to break in help | 17 | 3w |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
In regards to research quality, you could look at the list of top sell-side analyst to see if the analyst you would be working for is on there. If I recall correctly, JPM sell-side analyst dominate a good portion of the list.
I don't know if London would be different, but in America, this is a no-brainer. JPM blows GS' research out of the water. Look at Institutional Investor for rankings.
Agreed with the above, JPM is a clear n1 in ER. GS has a better name if you want to do IB down the line although it’s relatively marginal. Would take JPM anyday, although being in the City in GS’s new offices would be much nicer
Do you think going somewhere that produces good research is necessary for career development/learning?
Depends what you want to do be it ER/AM/HF or something outside in the long run and if you have sector preferences
A little late to this, but I would make my decision based off the analyst. It's different than banking where certain firms are respected. There are analysts at good firms that are terrible and vice versa. When you're looking for exit ops, the buy side will definitely look at the analyst that you worked for.
All that said, JPM generally has more II analysts than Goldman (and the rest of the street for that matter).
Goldman doesn't participate in II rankings so anyone who touts the "GS doesn't have many II analysts ergo they are bad" has no idea what he's talking about.
That said JPM>GS for ER
JPM every day of the week and twice on sundays. They are by far and away the best ER shop on the Street. Goldman, despite being top tier in everything else, is mediocre at best in research - and it’s not because they can’t be, it’s a business decision. Research is a loss leader business and GS stopped trying to compete years ago because they make more in IBD and Trading.
Source: worked BB S&T for 2 yrs
Aliquam eveniet molestiae excepturi architecto consequuntur quasi. Debitis repellat repellendus cumque perferendis quia. Consequatur est quod magni aut. Saepe et quis et quos repellendus.
Beatae sint iusto excepturi in fugiat optio consequatur. Nobis quibusdam qui consequatur eos. Officiis fuga doloremque aliquid quae doloremque tenetur. Voluptatem eius odit architecto.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...